Y
Yves Pommier
Researcher at National Institutes of Health
Publications - 847
Citations - 65543
Yves Pommier is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Topoisomerase & DNA. The author has an hindex of 123, co-authored 789 publications receiving 58898 citations. Previous affiliations of Yves Pommier include Purdue University & Kyushu University.
Papers
More filters
Journal ArticleDOI
Synthesis and Evaluation of Indenoisoquinoline Topoisomerase I Inhibitors Substituted with Nitrogen Heterocycles
Muthukaman Nagarajan,Andrew Morrell,Alexandra Ioanoviciu,Smitha Antony,Glenda Kohlhagen,Keli Agama,Melinda Hollingshead,Yves Pommier,Mark Cushman +8 more
TL;DR: Molecular modeling of these compounds in complex with DNA and Top1 suggests that some of the lactam substituents are capable of interacting with the DNA base pairs above and below the site of intercalation and/or with Top1 amino acid residues, resulting in increased biological activity.
Journal ArticleDOI
Analysis of ATP-binding cassette transporter expression in drug-selected cell lines by a microarray dedicated to multidrug resistance.
Jean Philippe Annereau,Gergely Szakács,Charles J. Tucker,Angela Arciello,Carol O. Cardarelli,Jennifer B. Collins,Sherry F. Grissom,Barry R. Zeeberg,William C. Reinhold,John N. Weinstein,Yves Pommier,Richard S. Paules,Michael M. Gottesman +12 more
TL;DR: It is demonstrated that ABC transporters show dramatic overexpression, whereas the glutathione S-transferase gene GST-Pi shows the strongest decrease in expression among the 20,000 genes studied.
Journal Article
Topoisomerase II-mediated DNA damage produced by 4'-(9-acridinylamino)methanesulfon-m-anisidide and related acridines in L1210 cells and isolated nuclei: relation to cytotoxicity.
TL;DR: Evidence is found for a causal relationship between drug-induced topoisomerase II-mediated DNA breaks and cytotoxicity between m-AMSA and several acridine analogues in adult acute leukemia.
Journal ArticleDOI
Apoptosis induced by DNA topoisomerase I and II inhibitors in human leukemic HL-60 cells.
TL;DR: Better understanding of the apoptotic regulation in the widely used and characterized HL-60 cell line should allow the identification of new mechanisms and parameters of cellular sensitivity and resistance to the cytotoxic activity of anticancer agents.
Journal ArticleDOI
Tyrosyl-DNA Phosphodiesterase 1 (Tdp1) inhibitors
TL;DR: Better understanding of Top1cc repair in vivo coupled with detailed structural studies on TDP1–inhibitor interaction will be crucial in guiding the rational design of Tdp1 inhibitors, which should synergize not only with Top1-targeting drugs, but also with bleomycin, topoisomerase II (Top2) inhibitors and DNA alkylating agents.